LOGIN
Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis
August 2017
Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
N Engl J Med. 2016 Oct 20;375(16):1532-1543Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
7180 postmenopausal women with osteoporosis were randomized to 12 months of treatment with either romosozumab or placebo, followed by a further 12 months of treatment with denosumab in both groups. The purpose of this study was to evaluate and compare vertebral fracture incidence, nonovertebral fracture incidence, and safety outcomes between groups after 6, 12, 18, and 24 months. Results after 12 ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.